» Articles » PMID: 8514446

Trk and Ret Proto-oncogene Expression in Human Neuroblastoma Specimens: High Frequency of Trk Expression in Non-advanced Stages

Overview
Journal Int J Cancer
Specialty Oncology
Date 1993 Jun 19
PMID 8514446
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Forty-three fresh tumor specimens of human neuroblastoma belonging to different clinical stages were analyzed for the expression of 2 proto-oncogenes: trk, which encodes a tyrosine-kinase receptor for nerve growth factor (NGF) and ret, another receptor-type tyrosine kinase whose ligand is unknown. The mRNA expression of the trk gene was detected in 67.4% of cases, with increased frequency in I, II and IVs Evans' stages and in patients with favorable prognosis according to the Shimada classification. Moreover, trk expression inversely correlated with Nmyc-gene amplification. ret mRNA was found in 36.8% of cases and equally distributed in the different stages. In addition, ngfR (low-affinity NGF receptor)-gene expression was present in 9 out of 25 cases. The simultaneous presence of mRNA related to both forms of the NGF receptor, while not proving the presence of a functional receptor, indicates the existence of a sub-set of neuroblastoma cells potentially responsive to NGF.

Citing Articles

Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.

Steen E, Basilaia M, Kim W, Getz T, Gustafson J, Zage P Biochem Pharmacol. 2023; 216:115751.

PMID: 37595672 PMC: 10911250. DOI: 10.1016/j.bcp.2023.115751.


Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.

Yan W, Lakkaniga N, Carlomagno F, Santoro M, McDonald N, Lv F J Med Chem. 2018; 62(4):1731-1760.

PMID: 30188734 PMC: 7875308. DOI: 10.1021/acs.jmedchem.8b01092.


(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.

Choi H, Rucker P, Wang Z, Fan Y, Albaugh P, Chopiuk G ACS Med Chem Lett. 2015; 6(5):562-7.

PMID: 26005534 PMC: 4434478. DOI: 10.1021/acsmedchemlett.5b00050.


Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.

Albaugh P, Fan Y, Mi Y, Sun F, Adrian F, Li N ACS Med Chem Lett. 2014; 3(2):140-5.

PMID: 24900443 PMC: 4025649. DOI: 10.1021/ml200261d.


Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.

DeNardo B, Holloway M, Ji Q, Nguyen K, Cheng Y, Valentine M PLoS One. 2013; 8(12):e82513.

PMID: 24349301 PMC: 3859635. DOI: 10.1371/journal.pone.0082513.